Randi Hagerman
Medical Director
MIND Institute
From this contributor
Diabetes drug delivers multiple benefits for people with fragile X syndrome
Researcher Randi Hagerman is a big proponent of metformin — a diabetes drug that she is testing in people with fragile X syndrome. In fact, Hagerman takes the drug herself as a preventive measure against cancer.
Diabetes drug delivers multiple benefits for people with fragile X syndrome
Drug trials for fragile X syndrome lead the way for autism
Several targeted trials on drugs that treat fragile X syndrome are under way. But accurate endpoints to measure the drugs’ effectiveness are crucial, argues developmental and behavioral pediatrician Randi Hagerman.
Drug trials for fragile X syndrome lead the way for autism
Explore more from The Transmitter
Is it time for neuroscience to shift its focus from a computational mind to a navigating mind?
Andrea Hiott explains her navigational approach to the mind, and why now is the time to embrace seemingly paradoxical findings in neuroscience.
Is it time for neuroscience to shift its focus from a computational mind to a navigating mind?
Andrea Hiott explains her navigational approach to the mind, and why now is the time to embrace seemingly paradoxical findings in neuroscience.
Human brain organoids come of age—but still have room to grow
The U.S. government has touted organoids as an alternative to animals for studying the brain. The model has improved since its debut in 2013, but scientists are still working to overcome key limitations: immaturity, consistency and the lack of vascularization.
Human brain organoids come of age—but still have room to grow
The U.S. government has touted organoids as an alternative to animals for studying the brain. The model has improved since its debut in 2013, but scientists are still working to overcome key limitations: immaturity, consistency and the lack of vascularization.
Finding neuroheterogeneity’s sweet spot
Once thought to be detrimental to memory processing, neuronal diversity—at the right ‘Goldilocks’ dose—is a new boon to theoretical neuroscience.
Finding neuroheterogeneity’s sweet spot
Once thought to be detrimental to memory processing, neuronal diversity—at the right ‘Goldilocks’ dose—is a new boon to theoretical neuroscience.